| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 102,254 | 120,989 | 116,743 | 102,692 |
| Cost of services | 34,043 | 36,721 | 32,216 | 31,790 |
| Gross profit | 68,211 | 84,268 | 84,527 | 70,902 |
| Selling and marketing | NaN | 27,131 | 23,510 | 19,448 |
| Research and development | 19,804 | 24,541 | 19,829 | 15,079 |
| General and administrative | NaN | 46,831 | 44,439 | 27,415 |
| Selling, general and administrative | 74,591 | NaN | NaN | NaN |
| Impairment loss | 31,287 | 0* | NaN | NaN |
| Other operating expenses, net | NaN | 0* | NaN | NaN |
| Loss from operations | -57,471 | -14,235 | -3,251 | 8,960 |
| Change in fair value of financial liabilities | 2,540 | 1,116 | -3,401 | 2,181 |
| Interest expense, net | -717 | -520 | -562 | -817 |
| Loss on extinguishment of debt | -6,565 | NaN | NaN | NaN |
| Other (expense) income, net | -206 | -4,591 | -174 | 239 |
| Total non-operating expense, net | -4,948 | -3,995 | -4,137 | 1,603 |
| Loss before income taxes | -62,419 | -18,230 | -7,388 | 10,563 |
| Income tax expense | 897 | -564 | 247 | -246 |
| Net loss | -63,316 | -17,666 | -7,635 | 10,809 |
| Unrealized (gain) loss related to available for sale securities, net | -253 | -66 | 190 | -93 |
| Comprehensive loss | -63,569 | -17,732 | -7,445 | 10,716 |
| Basic EPS | -2.16 | -0.611 | -0.27 | 0.38 |
| Diluted EPS | -2.16 | -0.636 | -0.27 | 0.36 |
| Basic Average Shares | 29,335,126 | 29,041,554 | 28,797,730 | 28,579,704 |
| Diluted Average Shares | 29,335,126 | 27,867,325 | 28,797,730 | 29,753,933 |
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)